Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01858558 · OUTCOME

Overall Survival (OS)

Tadalafil and Lenalidomide Maintenance With or Without Activated Marrow Infiltrating Lymphocytes (MILs) in High Risk Myeloma · Source last updated 2020-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
3 years

What was measured

OS assessed by number of participants alive at the end of follow up period.

Analysis population: This is an analysis by intention-to-treat and only considers transplanted patients randomized to the aMILs arm.

Groups in this outcome

aMIL Arm

Patients receive activated Marrow Infiltrating Lymphocytes (aMIL) aMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
aMIL Arm70

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
aMIL Arm55Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        55
denoms
  1. counts
    1. group Id
      OG000
      value
      70
    units
    Participants
description
OS assessed by number of participants alive at the end of follow up period.
groups
  1. description
    Patients receive activated Marrow Infiltrating Lymphocytes (aMIL) aMIL: On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
    id
    OG000
    title
    aMIL Arm
param Type
COUNT_OF_PARTICIPANTS
population Description
This is an analysis by intention-to-treat and only considers transplanted patients randomized to the aMILs arm.
reporting Status
POSTED
time Frame
3 years
title
Overall Survival (OS)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice